← Back to Search

Antibiotic

Minocycline for Stroke

Phase 2
Waitlist Available
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age of 18 to 85 years
Diagnosis of ruptured cerebral aneurysm
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured baseline at time of enrollment and every other day until 14 days
Awards & highlights

Study Summary

This trialaims to determine if MMP9 levels can predict vasospasm in aneurysm patients, and investigate minocycline as a possible treatment to improve outcomes and reduce hospital stays.

Who is the study for?
This trial is for adults aged 18 to 85 who have had a ruptured cerebral aneurysm and can start the trial within 24 hours of the rupture. It's not suitable for those allergic to tetracycline, pregnant individuals, or people with liver or kidney failure.Check my eligibility
What is being tested?
The MASH trial is testing whether minocycline, which inhibits MMP9 (a molecule involved in brain damage after bleeding), can predict and reduce complications from blood vessel spasms after a brain hemorrhage due to aneurysm rupture.See study design
What are the potential side effects?
Minocycline may cause side effects like dizziness, fatigue, gastrointestinal issues, skin reactions, and possibly affect liver enzymes. The severity of these side effects varies among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 85 years old.
Select...
I have had a ruptured brain aneurysm.
Select...
I was enrolled in the study within a day of my rupture.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured baseline at time of enrollment and every other day until 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured baseline at time of enrollment and every other day until 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood brain barrier permeability
Secondary outcome measures
Onset of cerebral vasospasm
Serum MMP9 levels

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
899 Previous Clinical Trials
1,595,293 Total Patients Enrolled

Media Library

Minocycline (Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT04876638 — Phase 2
Blood-Brain Barrier Dysfunction Research Study Groups:
Blood-Brain Barrier Dysfunction Clinical Trial 2023: Minocycline Highlights & Side Effects. Trial Name: NCT04876638 — Phase 2
Minocycline (Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04876638 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~9 spots leftby Dec 2027